Breakthrough in Metabolic Research

The human body’s ability to adapt to calorie restriction has long been a barrier to sustained weight loss. As individuals reduce their caloric intake, metabolism slows to conserve energy—a survival mechanism that undermines dieting efforts. A groundbreaking study from the University of Southern Denmark, published in Cell Metabolism, has identified a potential solution to this problem by targeting a gene called Plvap in liver cells^1,2. This discovery not only sheds light on the liver’s role in metabolic adaptation but also opens avenues for enhancing the efficacy of weight-loss medications like Wegovy and Ozempic. By manipulating Plvap, researchers successfully maintained calorie-burning rates in mice during fasting, offering hope for overcoming weight loss plateaus and improving metabolic health in humans.

The Challenge of Metabolic Adaptation

When the body perceives a calorie deficit, it triggers a series of adaptations to preserve energy. This evolutionary response, often called “starvation mode,” reduces metabolic rate and prioritizes fat storage, making further weight loss increasingly difficult¹. For users of GLP-1 agonists such as Wegovy, this adaptation typically halts progress after a 20–25% reduction in body weight^1,2. Associate Professor Kim Ravnskjaer, lead author of the study, explains: “The body’s metabolism adapts to weight loss, effectively hitting the brakes on calorie burning. This is why progress stalls despite continued dieting or medication”¹.

The liver plays a central role in this process. During fasting or calorie restriction, it shifts from burning glucose to fatty acids, a transition mediated by hormonal and cellular signals. However, the exact mechanisms governing this metabolic switch have remained unclear—until now.

The Plvap Gene: A Metabolic Gatekeeper

The research team initially focused on Plvap, a gene linked to lipid metabolism in mammals. Previous studies had shown that humans lacking this gene exhibit lipid-processing abnormalities, prompting further investigation^1,2. In mice, Plvap was found to be expressed in stellate cells, a type of liver cell not previously associated with metabolic regulation¹.

Stellate Cells: Unexpected Regulators of Metabolism

When the researchers deactivated Plvap in stellate cells, they observed a remarkable phenomenon: the liver no longer recognized fasting conditions. Normally, fasting triggers the liver to switch from glucose to fat metabolism, producing ketones as an alternative energy source. However, in Plvap-deficient mice, this shift failed to occur. Instead, the liver continued burning glucose, even as fatty acids were released into the bloodstream^1,2.

“The liver essentially ‘thinks’ it’s not fasting,” Ravnskjaer notes. “By disrupting Plvap, we bypassed the metabolic slowdown typically seen during calorie restriction”¹.

Fat Redirection and Improved Insulin Sensitivity

Surprisingly, the absence of Plvap did not lead to harmful fat accumulation in the liver. Instead, fatty acids were redirected to skeletal muscles, where they were efficiently metabolized. The mice exhibited improved insulin sensitivity and lower blood sugar levels—key benefits for individuals with type 2 diabetes^1,2. This finding challenges the conventional view that fat must be processed by the liver during fasting and suggests alternative pathways for nutrient utilization.

Implications for Obesity and Diabetes Treatment Enhancing Weight-Loss Medications

Drugs like Wegovy (semaglutide) work by suppressing appetite and slowing gastric emptying, but their effectiveness diminishes as metabolism adjusts. The study proposes that targeting Plvap could maintain high rates of fat and sugar oxidation, allowing patients to surpass weight-loss plateaus^1,2. “If we can develop a drug that sustains the liver’s calorie-burning capacity, it could complement existing therapies,” says Ravnskjaer¹.

A New Approach to Diabetes Management

Elevated blood sugar is a hallmark of type 2 diabetes and a driver of complications such as neuropathy and retinopathy. By preventing the liver from overproducing glucose during fasting, Plvap modulation could offer better glycemic control. The improved insulin sensitivity observed in mice further underscores its therapeutic potential¹.

From Mice to Humans: A Long Road Ahead

While these findings are promising, the research remains in its early stages. The study was conducted exclusively in mice, and translating these results to humans will require extensive clinical trials. Ravnskjaer cautions: “There’s a vast difference between mouse models and human biology. A Plvap-targeting drug is likely decades away, but the mechanistic insights are transformative”¹.

Unanswered Questions and Future Directions

Key unknowns include the long-term effects of Plvap inhibition and whether similar metabolic benefits can be achieved without genetic modification. The team also aims to explore how stellate cells communicate with other liver cells to regulate metabolism—a discovery that could reveal additional therapeutic targets^1,2.

Rethinking Liver Biology

The study’s most profound contribution may lie in its redefinition of liver function. Stellate cells, traditionally studied for their role in fibrosis, now emerge as metabolic regulators. By secreting signals that coordinate the fasting response, these cells act as conductors of liver metabolism, directing hepatocytes to switch fuel sources^1,2. This paradigm shift highlights the complexity of intercellular communication and opens new avenues for treating metabolic diseases.

Conclusion

The University of Southern Denmark’s research offers a groundbreaking strategy to counteract metabolic adaptation, a major obstacle in obesity treatment. By identifying Plvap as a critical mediator of the liver’s fasting response, the study paves the way for therapies that sustain calorie burning during dieting. While clinical applications remain distant, this work deepens our understanding of metabolic regulation and underscores the potential of targeting non-traditional cell types like stellate cells. For millions struggling with weight plateaus or diabetes, these findings represent a beacon of hope—one that could transform the landscape of metabolic disease management.

“This isn’t just about weight loss,” Ravnskjaer concludes. “It’s about reprogramming metabolism to improve health outcomes across chronic diseases”¹.

Citations:

1. https://www.news-medical.net/news/20250303/Breakthrough-research-uncovers-way-to-maintain-metabolism-during-calorie-restriction.aspx
2. https://www.eurekalert.org/news-releases/1074818
3. https://portal.findresearcher.sdu.dk/en/publications/hepatic-stellate-cells-regulate-liver-fatty-acid-utilization-via-
4. https://newatlas.com/diet-nutrition/tricking-metabolism-weight-loss/
5. https://colab.ws/researchers/28339
6. https://www.sdu.dk/en/atlas/news/hepatic-stellate-cells-control-liver-metabolism
7. https://www.sdu.dk/en/om-sdu/fakulteterne/naturvidenskab/nyheder/fedt-stofskifte-kim-ravnskjaer
8. https://nypost.com/2025/03/03/health/scientists-figured-out-how-to-trick-metabolism-for-weight-loss/
9. https://patienttalk.org/unveiling-metabolisms-secrets-how-to-trick-your-body-into-burning-more-calories/
10. https://x.com/ravnskjaer_lab?lang=en
11. https://pubmed.ncbi.nlm.nih.gov/40037362/
12. https://biopharmbiz.substack.com/p/new-research-suggests-ways-to-trick?action=share
13. https://x.com/ThanhTungTrann/status/1897170957514723596